Document is current
Any future updates will be listed below
-
Authors
Rius-Rocabert, Sergio
Tur-Planells, Vicent
Arranz-Herrero, Javier
Inchausti-Moya, Ines
Miorin, Lisa
de Luis, Enrique Vazquez
Dopazo, Ana
Solera, Ricardo Arroyo
Concepcion, Axel R.
Gastaminza, Pablo
García-Sastre, Adolfo
Nistal-Villan, Estanislao
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (PID2019-105761RB-100)
- License Information
-
More Information
Article History
Received: 13 September 2025
Accepted: 14 March 2026
First Online: 29 April 2026
Declarations
:
: The A.G.-S. laboratory has received research support from Avimex, Dynavax, Pharmamar, 7Hills Pharma, ImmunityBio and Accurius, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer, Virofend and Prosetta, outside of the reported work. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott, Astrazeneca and Novavax. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside of the reported work.
